Genetic variability and transplantation

Current Opinion in Urology

Volumn 13, Issue 2, 2003, Pages 81-89

  Marder, Brad ^a   Schröppel, Bernd ^a   Murphy, Barbara ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute rejection; Gene polymorphisms; Genetic variability; Graft survival; Transplantation

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE;

BLOOD CLOTTING; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY TRANSPLANTATION; MOLECULE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; ANTIGENS, CD; CELL ADHESION MOLECULES; CHEMOKINES; CYTOKINES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 0037336642     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200303000-00001     Document Type: Review

References (91)

1. Asano H, Kobayashi T, Uchida K, et al. Significance of tumor necrosis factor microsatellite polymorphism in renal transplantation. Tissue Antigens 1997; 50:484-488.
2. Hahn AB, Kasten-Jolly JC, Constantino DM, et al. TNF-alpha, IL-6, IFN-gamma, and IL-10 gene expression polymorphisms and the IL-4 receptor alpha-chain variant Q576R: effects on renal allograft outcome. Transplantation 2001; 72:660-665.
3. Pelletier R, Pravica V, Perrey C, et al. Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 2000; 70:674-680.
4. Poli F, Boschiero L, Giannoni F, et al. Tumour necrosis factor-alpha gene polymorphism: implications n kidney transplantation. Cytokine 2000; 12:1778-1783.
5. Sankaran D, Asderakis A, Ashraf S, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 1999; 56:281-288.
6. Hutchings A, Guay-Woodford L, Thomas JM, et al. Association of cytokine single nucleotide polymorphisrns with B7 costimulatory molecules in kidney allograft recipients. Pediatr Transplant 2002; 6:69-77. This study found a significant link between an IL-10 genotype and acute kidney rejection that was limited to African Americans. In addition to this interesting association with ethnicity, the authors demonstrated a functional correlation with costimulatory molecule expression.
7. Marshall SE, McLaren AJ, Haldar NA, et al. The impact of recipient cytokine genotype on acute rejection after renal transplantation. Transplantation 2000; 70:1485-1491.
8. Muller-Steinhardt M, Hartel C, Muller B, et al. The interleukin-6 -174 promoter polymorphism is associated with long-term kidney allograft survival. Kidney Int 2002; 62:1824-1827.
9. Poole KL, Gibbs PJ, Evans PR, et al. Influence of patient and donor cytokine genotypes on renal allograft rejection: evidence from a single centre study. Transpl Immunol 2001; 8:259-265.
10. Marshall SE, McLaren AJ, McKinney EF, et al. Donor cytokine genotype influences the development of acute rejection after renal transplantation. Transplantation 2001; 71:469-476.
11. Fernandes H, Koneru B, Fernandes N, et al. Investigation of promoter polymorphisms in the tumor necrosis factor-alpha and interleukin-10 genes in liver transplant patients. Transplantation 2002; 73:1886-1891.
12. Bathgate AJ, Pravica V, Perrey C, et al. The effect of polymorphisms in tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in acute hepatic allograft rejection. Transplantation 2000; 69:1514-1517.
13. Turner D, Grant SC, Yonan N, et al. Cytokine gene polymorphism and heart transplant rejection. Transplanlation 1997; 64:776-779.
14. Abdallah AN, Cucchi-Mouillot P, Biteau N, et al. Analysis of the polymorphism of the tumour necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe rejection. Eur J Immunogenet 1999; 26:249-255.
15. Mahoney RJ, Szatkowski MA, White BA, Leeber DA. Tumor necrosis factor beta gene polymorphism and early primary kidney allograft loss. Hum Immunol 1996; 50:148-150.
16. Cartwright NH, Keen LJ, Demaine AG, et al. A study of cytokine gene polymorphisms and protein secretion in renal transplantation. Transpl Immunol 2001; 8:237-244.
17. Hackstein H, Kluter H, Fricke L, et al. The IL-4 receptor alpha-chain variant Q576R is strongly associated with decreased kidney allograft survival. Tissue Antigens 1999; 54:471-477.
18. Abdi R, Tran TB, Sahagun-Ruiz A, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002; 13:754-758.
19. Kruger B, Schroppel B, Ashkan R, et al. A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 2002; 13:2585-2589. This is the first study showing an association of individual chemokines with outcome in kidney transplantation. Clinical findings are supported by well designed functional experiments.
20. Schroppel B, Fischereder M, Ashkar R, et al. The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant 2002; 2:640-645.
21. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357:1758-1761. This study genotyped a large cohort of kidney transplant recipients for the rare CCR5Δ32 mutation. The presence of this loss of function mutation resulted in a significantly prolonged allograft half-life, as compared with the heterozygous or wild-type allele.
22. Schroppel B, Fischereder M, Lin M, et al. Analysis of gene polymorphisms in the regulatory region of MCP-1, RANTES, and CCR5 in liver transplant recipients. J Clin Immunol 2002; 22:381-385. This is a well powered study that notes an important lack of association of MCP-1 and CCR5 polymorphisms with graft outcome in liver transplantation. These results contrast with the positive associations for kidney transplantation, implying an organ-specific role for these polymorphisms.
23. McLaren AJ, Marshall SE, Haldar NA, et al. Adhesion molecule polymorphisms in chronic renal allograft failure. Kidney Int 1999; 55:1977-1982.
24. Borozdenkova S, Smith J, Marshall S, et al. Identification of ICAM-1 polymorphism that is associated with protection from transplant associated vasculopathy after cardiac transplantation. Hum Immunol 2001; 62:247-255.
25. Marder BA, Schroppel B, Lin M, et al. CTLA-4 and CD28 gene polymorphisms influence on kidney and liver allograft survival. J Am Soc Nephrol 2002; 13:13A (Free communication F-FC060)
26. Slavcheva E, Albanis E, Jiao Q, et al. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to acute allograft rejection. Transplantation 2001; 72:935-940. This is the first study looking at acute transplant rejection and costimulatory molecule polymorphisms. The authors examine two CTLA-4 polymorphisms with well known associations with autoimmune diseases.
27. Abdi R, Tran TB, Zee R, et al. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation 2001; 72:726-729.
28. Barocci S, Ginevri F, Valente U, et al. Correlation between angiotensin-converting enzyme gene insertion/deletion polymorphism and kidney graft long-term outcome in pediatric recipients: a single-center analysis. Transplantation 1999; 67:534-538.
29. Broekroelofs J, Stegeman CA, Navis G, et al. Risk factors for long-term renal survival after renal transplantation: a role for angiotensin-converting enzyme (insertion/deletion) polymorphism? J Am Soc Nephrol 1998; 9:2075-2081.
30. Viklicky O, Hubacek JA, Pitha J, et al. ACE gene polymorphism and long-term renal graft function. Clin Biochem 2001; 34:87-90.
31. Beige J, Scherer S, Weber A, et al. Angiotensin-converting enzyme genotype and renal allograft survival. J Am Soc Nephrol 1997; 8:1319-1323.
32. Beige J, Offermann G, Distler A, Sharma AM. Angiotensin-converting-enzyme insertion/deletion genotype and long-term renal allograft survival. Nephrol Dial Transplant 1998; 13:735-738.
33. Nicod J, Richard A, Frey FJ, Ferrari P. Recipient RAS gene variants and renal allograft function. Transplantation 2002; 73:960-965.
34. Yildiz A, Yazici H, Cine N, et al. The effect of angiotensin converting enzyme gene polymorphism on chronic allograft dysfunction in living donor renal transplant recipients. Clin Transplant 2002; 16:173-179.
35. Cunningham DA, Crisp SJ, Barbir M, et al. Donor ACE gene polymorphism: a genetic risk factor for accelerated coronary sclerosis following cardiac transplantation. Eur Heart J 1998; 19:319-325.
36. Pethig K, Heublein B, Hoffmann A, et al. ACE-gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients. J Heart Lung Transplant 2000; 19:1175-1182.
37. Wuthrich RP. Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis. Curr Opin Nephrol Hypertens 2001; 10:409-414.
38. Ekberg H, Svensson PJ, Simanaitis M, Dahlback B. Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. Transplantation 2000; 69:1577-1581.
39. Hocher B, Slowinski T, Hauser I, et al. Association of factor V Leiden mutation with delayed graft function, acute rejection episodes and long-term graft dysfunction in kidney transplant recipients. Thromb Haemost 2002; 87:194-198. This is a large, well controlled study investigating many different relevant endpoints including delayed graft function, acute rejection, and chronic graft dysfunction.
40. Irish AB, Green FR, Gray DW, Morris PJ. The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation 1997; 64:604-607.
41. Hirshfield G, Collier JD, Brown K, et al. Donor factor V Leiden mutation and vascular thrombosis following liver transplantation. Liver Transpl Surg 1998; 4:58-61.
42. Fischereder M, Schneeberger H, Lohse P, et al. Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene. Am J Kidney Dis 2001; 38:1061-1064. As in the studies for factor V protein C resistance, the finding of clinical significance for the prothrombin 20210G/A SNP supports screening in patients with a known history of thrombosis.
43. Salido E, Martin B, Barrios Y, et al. The PIA2 polymorphism of the platelet glycoprotein IIIA gene as a risk factor for acute renal allograft rejection. J Am Soc Nephrol 1999; 10:2599-2605.
44. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13:260-264. This is an interesting study describing the significance of two polymorphisms in the VEGF gene for acute rejection risk in kidney transplants. The study provides good functional data supporting the clinical findings.
45. Beige J, Engeli S, Ringel J, et al. Donor G protein beta3 subunit 825TT genotype is associated with reduced kidney allograft survival. J Am Soc Nephrol 1999; 10:1717-1721.
46. Hocher B, Pleschka A, Yang F, et al. G protein beta3 subunit 825T genotype is not associated with differing outcome in pediatric renal transplant recipients. Pediatr Transplant 2002; 6:141-146.
47. Wuthrich RP, Cicvara S, Booy C, et al. The 825C/T polymorphism of the G-protein subunit beta3 does not influence blood pressure and renal function in kidney transplant recipients. Nephrol Dial Transplant 2000; 15:1663-1666.
48. Hagen W, Fodinger M, Heinz G, et al. Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. Kidney Int Suppl 2001; 78:S253-S257.
49. Liangos O, Kreutz R, Beige J, et al. Methylenetetrahydrofolate-reductase gene C677T variant and kidney-transplant survival. Nephrol Dial Transplant 1998; 13:2351-2354.
50. Heidenreich S, Lang D, Tepel M, Rahn KH. Monocyte activation for enhanced tumour necrosis factor-alpha and interleukin 6 production during chronic renal allograft rejection. Transpl Immunol 1994; 2:35-40.
51. McLaughlin PJ, Aikawa A, Davies HM, et al. Evaluation of sequential plasma and urinary tumor necrosis factor alpha levels in renal allograft recipients. Transplantation 1991; 51:1225-1229.
52. Platz KP, Mueller AR, Rossaint R, et al. Cytokine pattern during rejection and infection after liver transplantation: improvements in postoperative monitoring? Transplantation 1996; 62:1441-1450.
53. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997; 94:3195-3199.
54. Bouma G, Crusius JB, Oudkerk Pool M, et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel disease. Scand J Immunol 1996; 43:456-463.
55. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
56. Cox ED, Hoffmann SC, DiMercurio BS, et al. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001; 72:720-726.
57. Hoffmann SC, Stanley EM, Cox ED, et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002; 2:560-567. This study demonstrates a clear influence of ethnicity on the allelic distribution of several important cytokine polymorphisms.
58. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376.
59. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology: XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52:145-176.
60. Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12:511-516.
61. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725.
62. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182:459-465.
63. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-413.
64. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541-547.
65. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381:434-438.
66. Lin H, Rathmell JC, Gray GS, et al. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med 1998; 188:199-204.
67. Szot GL, Zhou P, Sharpe AH, et al. Absence of host B7 expression is sufficient for long-term murine vascularized heart allograft survival. Transplantation 2000; 69:904-909.
68. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-lg and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997; 94:8789-8794.
69. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4lg in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159:5187-5191.
70. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A 1992; 89:11102-11105.
71. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993; 290 (Pt 1):33-40.
72. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332:706-711.
73. Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330:1634-1638.
74. Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99:1786-1797.
75. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71:169-180.
76. Kunz R, Kreutz R, Beige J, et al. Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal. Hypertension 1997; 30:1331-1337.
77. Beige J, Weber A, Engeli S, et al. Angiotensinogen-M235T genotype and post-transplant hypertension. Nephrol Dial Transplant 1996; 11:1538-1541.
78. Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24:63-69.
79. Brand E, Chatelain N, Mulatero P, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998; 32:198-204.
80. Davies E, Holloway CD, Ingram MC, et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999; 33:703-707.
81. Heidenreich S, Dercken C, August C, et al. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol 1998; 9:1309-1313.
82. Wuthrich RP, Cicvara-Muzar S, Booy C, Maly FE. Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft toss. Transplantation 2001; 72:549-550.
83. Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001; 276:7614-7620.
84. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999; 48:1131-1137.
85. Schunkert H, Hense HW, Doring A, et al. Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998; 32:510-513.
86. Siffert W, Rosskopf D, Siffert G, et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18:45-48.
87. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
88. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93:7-9.
89. Kang SS, Wong PW, Susmano A, et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48:536-545.
90. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149-1155.
91. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111-128.